Abstract

Research Article

Serum Levels of the C-terminal Fragment of Fibroblast Growth Factor 23 (C-FGF23) and Hepcidin in Patients with Hemodialysis Undergoing Treatment with a Proline Hydroxylase Domain (PHD) Inhibitor

Yoshihiro Motomiya*, Yoshiteru Kaneko, Yasuki Motomiya and Yuichiro Higashimoto*

Published: 14 October, 2024 | Volume 8 - Issue 3 | Pages: 132-137

Background: We previously reported, for the first time, serum levels of the C-terminal fragment of fibroblast growth factor 23 (C-FGF23) in patients undergoing hemodialysis (HD). Most HD patients have undergone treatment with either recombinant erythropoietin (r-EPO) or hypoxia-inducible factor (HIF) proline hydroxylase domain (PHD) inhibitor, both of which stimulate FGF23 production and cleavage. 
Methods: This cross-sectional observational study involved analyzing measuring FGF-related parameters and comparing results for subgroups of patients who received either r-EPO and or a PHD inhibitor. 
Results: No significant difference was observed for iron-related parameters or serum hepcidin levels in both subgroups of patients. Significant differences were found for certain FGF-23-related parameters. 
Conclusion: Both FGF23 production and cleavage were stimulated more in patients treated with the PHD inhibitor than in patients treated with r-EPO.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001141 Cite this Article Read Full Article PDF

Keywords:

Fibroblast growth factor 23; FGF23; C-terminal fragment; Hemodialysis; Hepcidin

References

  1. Rankin ER, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068-1077. Available from: https://doi.org/10.1172/jci30117
  2. Zhang Q, Doucel M, Tomlinson RE, Han X, Quarles LD, Collins MT, et al. The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 2016;4:16011. Available from: https://doi.org/10.1038/boneres.2016.11
  3. MacMahon S, Gorondin F, McDonald PP, Richard DE, Dubois CM. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1. J Biol Chem. 2005;280:6561-6569. Available from: https://doi.org/10.1074/jbc.m413248200
  4. Daryadel A, Bettoni C, Haider T, Siva PI, Schnitzbauer U, Pastor-Arroyo EM, et al. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch. 2018;470:1569-82. Available from: https://doi.org/10.1007/s00424-018-2171-7
  5. Toro I, Barrientos V, Leon P. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2017;93:1131-1141. Available from: https://doi.org/10.1016/j.kint.2017.11.018
  6. Kautz M, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678-684. Available from: https://doi.org/10.1038/ng.2996
  7. Courbon G, Thomas JJ, Martinez-Calle M, Wang X, Spinde J, Drasek JV, Hunt-Tobey B, Mehta R, Isakova T, Chang W, Ceemers JWM, Ji P, Martin A, David V. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation. Blood. 2023;142:106-118. Available from: https://doi.org/10.1182/blood.2022018475
  8. Tanaka K, Higashimoto Y, Tomizawa M, Motomiya Y, Kaneko Y. Circulating levels of fibroblast growth factor 23 selective for C-terminal (FGF23-CT) in hemodialysis patients. J Clin Nephrol. 2023;7:085-91. Available from: https://doi.org/10.29328/journal.jcn.1001115
  9. Motomiya Y, Kaneko Y, Higashimoto Y. Clinical usefulness of the serum-soluble transferrin receptor in iron dysregulation associated with long-term hemodialysis. Int J Clin Case Rep Rev. 2024;17(2):[Epub ahead of print]. Available from: https://www.auctoresonline.org/uploads/articles/1714397129IJCCR-24-RA-430-Galley_Proof.pdf
  10. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289:9795-9810. Available from: https://doi.org/10.1074/jbc.m113.527150
  11. Goetz R, Nakada Y, Hu MC, Mohammadi M. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2009;107:407-412. Available from: https://doi.org/10.1073/pnas.0902006107
  12. Agoro R, Montagna A, Goetz R, Allegbe O, Singh G, Coe LM, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J. 2018;32:3752-3764. Available from: https://doi.org/10.1096/fj.201700667r
  13. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008;142:669-671. Available from: https://doi.org/10.1111/j.1365-2141.2008.07225.x
  14. Nemeth E, Rivera S, Gabayan Y, Keller C, Taudorf S, Pederson BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276. Available from: https://doi.org/10.1172/jci20945
  15. Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36:87-93. Available from: https://doi.org/10.1016/j.semnephrol.2016.02.001
  16. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985-996. Available from: https://doi.org/10.1016/j.kint.2016.05.019
  17. Flamme I, Ellinghaus P, Urrego D, Krüger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One. 2017;12. Available from: https://doi.org/10.1371/journal.pone.0186979
  18. van Vuren AJ, Gaillard CJM, Eisenga MF, van Wijk R, van Beers E. The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research. Front Physiol. 2019;10:304. Available from: https://doi.org/10.3389/fphys.2019.00304
  19. Las Rivas M, Daniel EJP, Narimatsu Y, Companon I, Kato K, Hemosilla P, et al. Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. Nat Chem Biol. 2020;16:351-360. Available from: https://doi.org/10.1038/s41589-019-0444-x
  20. Hanudel MR, Eisenga M, Rappaport M, Chua K, Qiao B, Jung G, et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019;34:2057-2065. Available from: https://doi.org/10.1093/ndt/gfy189

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?